Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma

by palligoelme@gmail.com | Sep 2, 2026 | Clinical Trials

​ Conditions: DLBCL; CLL; FL; MCL; WM; MZL Interventions: Drug: BAFF-R CAR-T Sponsors: Institute of Hematology & Blood Diseases Hospital, China; Hebei Taihe Chunyu Biotechnology Co., Ltd Not yet recruiting Conditions: DLBCL; CLL; FL; MCL; WM; MZL Interventions:...

Deconstructing Maternal Burdens: Doulas and the Community Unite for Health

by palligoelme@gmail.com | Sep 2, 2026 | Clinical Trials

​ Conditions: Pregnancy; Post Partum; Doula Care; Postpartum Depression (PPD); Perinatal Depression; Perinatal Anxiety; Health Disparities; Pregnancy Complications; Maternal Adverse Outcomes Interventions: Other: Doula; Other: Standard (non-enhanced) Medicaid doula...

Hemoglobin Disorders in Egypt: Sickle Cell Disease Ain Shams University Institutional Registry

by palligoelme@gmail.com | Sep 2, 2026 | Clinical Trials

​ Conditions: Sickle Cell Disease (SCD) Sponsors: Ain Shams University Recruiting Conditions: Sickle Cell Disease (SCD) Sponsors: Ain Shams University Recruiting 

Implementation-effectiveness Trial of Mainstreaming of Clinical Genomic Sequencing for Rare Disease in Ontario, Canada

by palligoelme@gmail.com | Sep 2, 2026 | Clinical Trials

​ Conditions: Evaluation of Mainstreamed Models of Genetic Service Delivery; Genetic Disease; Neurodevelomental Disorders Interventions: Genetic: Genome-wide Sequencing Ordering Sponsors: The Hospital for Sick Children Not yet recruiting Conditions: Evaluation of...

Brivaracetam Bioequivalence Assessment

by palligoelme@gmail.com | Sep 2, 2026 | Clinical Trials

​ Conditions: Bioequivalence Study in Healthy Subjects Interventions: Drug: Briveka ® 100 mg; Drug: Briviact® 100 mg Sponsors: Zodiac Produtos Farmaceuticos S.A. Completed Conditions: Bioequivalence Study in Healthy Subjects Interventions: Drug: Briveka ® 100 mg;...

A Clinical Study To Evaluate The Performances of A Pulsed Electric Field Ablation Through Percutaneous Approach for Patients With Early-Stage Lung Cancer or Lung Oligometastatic Tumor.

by palligoelme@gmail.com | Sep 2, 2026 | Clinical Trials

​ Conditions: Lung Cancer (NSCLC) Interventions: Device: Pulsed Electric Field Ablation Sponsors: Energenx Medical LTD. Not yet recruiting Conditions: Lung Cancer (NSCLC) Interventions: Device: Pulsed Electric Field Ablation Sponsors: Energenx Medical LTD. Not yet...